Jiangsu Lianhuan Pharmaceutical Co., Ltd. annonce que sa filiale détenue en majorité a obtenu l'« Avis d'approbation de la demande complémentaire de médicament ».

Securities Code: 600513 Securities Abbreviation: Lianhuan Pharmaceutical Announcement Number: 2026-012

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Announcement on the Approval of the Supplementary Drug Application by the Controlling Subsidiary

The Board of Directors of the Company and all Directors guarantee that there are no false records, misleading statements, or significant omissions in the content of this announcement and assume legal responsibility for the authenticity, accuracy, and completeness of its content.

Jiangsu Lianhuan Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) controlling subsidiary Xinxiang Changle Pharmaceutical Co., Ltd. (hereinafter referred to as “Changle Pharmaceutical”) recently received the “Approval Notice for Supplementary Drug Application” for Nicorandil Tablets (hereinafter referred to as “this product” or “the drug”) issued by the National Medical Products Administration (hereinafter referred to as “NMPA”). The relevant situation is now announced as follows:

I. Basic Information of the Drug

■

II. Other Information of the Drug

Nicorandil Tablets are used for the treatment of angina pectoris. As of the date of this announcement, the estimated sales in domestic sample hospitals for this drug in 2024 is approximately 635 million yuan (data sourced from Morpheus Pharmaceutical Database).

As of the date of this announcement, Changle Pharmaceutical has invested approximately 7.2 million yuan in the research and development of this drug (unaudited).

As of the date of this announcement, this is the first production approval obtained by Changle Pharmaceutical in 2026.

III. Impact on the Company and Risk Warning

The approval of the “Approval Notice for Supplementary Drug Application” for Nicorandil Tablets by Changle Pharmaceutical further enriches the product variety of the Company and its subsidiaries, which is beneficial for enhancing the market competitiveness of the Company and its subsidiaries. The acquisition of the above-mentioned “Approval Notice for Supplementary Drug Application” is not expected to have a significant impact on the recent operating performance of the Company and its subsidiaries. Due to the influence of national policies, market conditions, market acceptance, market competitiveness, and other factors on drug sales, there is uncertainty. Investors are advised to make prudent decisions and pay attention to investment risks.

This announcement is hereby made.

Board of Directors of Jiangsu Lianhuan Pharmaceutical Co., Ltd.

March 27, 2026

Massive information, precise interpretation, all in the Sina Finance APP